- Trial phase
- Phase 1
- Time to market
- If successful through all clinical phases, potential approval would likely be many years away (approximately 2029-2031 at the earliest), as the drug is just entering Phase 1 dose-escalation studies.
- Why 2/10
- MGC030 just entered Phase 1 (first patient dosed October 15, 2026) with no scheduled binary catalyst in the next 12 months; no PDUFA date, pivotal readout, or regulatory decision applies. The drug is one of several early-stage pipeline assets at a company whose value is driven primarily by MGC026.
MGC030 is in very early-stage Phase 1 dose escalation with no interim data or binary catalyst on the calendar. Watch for any initial safety and pharmacokinetic data readouts, likely in late 2027 or 2028. The more impactful near-term catalyst for MGNX is the next MGC026 data update anticipated mid-2027. MGC030 alone is unlikely to move the stock meaningfully in the next 12 months.
Price Chart
Executive Summary
MGC030 is an early-stage antibody-drug conjugate (ADC) from MacroGenics (MGNX) that targets an undisclosed antigen expressed on multiple solid tumor types. The company dosed the first patient in a Phase 1 study in October 2026, meaning the drug is at the very start of clinical development with no efficacy or safety data reported yet. MGC030 is one of several pipeline programs at MacroGenics, following behind the company's lead B7-H3 ADC MGC026 (which reported encouraging Phase 1 data at ESMO 2026). With a current stock price of $2.20, analyst mean price target of $8.00 (implying ~264% upside), and $288M in cash providing runway through 2028, MGC030 is a very early-stage, high-risk/high-reward pipeline asset that is unlikely to drive near-term stock movement on its own.
How It Works
MGC030 is an antibody-drug conjugate (ADC), a type of targeted cancer therapy that works like a guided missile. It consists of an antibody (the 'guidance system') that binds to a specific protein found on the surface of solid tumor cells, linked to a potent chemotherapy drug (the 'warhead'). The antibody seeks out cancer cells, binds to them, and delivers the chemotherapy directly inside the cell, aiming to kill tumors while sparing healthy tissue. MacroGenics has not disclosed which specific protein (antigen) MGC030 targets.
Trial Status
First patient dosed October 15, 2026 in a Phase 1 dose-escalation study for advanced solid tumors. No interim data have been reported. The study is actively enrolling.
The Two-Sided Case
Upcoming Catalysts
- No scheduled catalysts for MGC030 in the next 12 months; initial Phase 1 dose-escalation data unlikely before late 2027 or 2028.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MacroGenics, Inc. PRESS-RELEASE MGNX ·Originating report